Immutep Reaches Enrolment Target for INSIGHT-003 Trial ...
Immutep Limited announced the INSIGHT-003 trial enrolled 20 patients with 1L NSCLC, testing efti in a triple therapy with anti-PD-1 and chemotherapy. Initial results show a 72.7% response rate and 90.9% disease control rate, with more data expected in 2023.
Reference News
Immutep Limited enrolled 20 patients in the INSIGHT-003 trial for 1st line non-small cell lung cancer, testing efti with anti-PD-1 therapy and chemotherapy. Initial results show a 72.7% response rate and 90.9% disease control rate, with more data expected in 2023.
Immutep Limited announced the INSIGHT-003 trial enrolled 20 patients with 1L NSCLC, testing efti in a triple therapy with anti-PD-1 and chemotherapy. Initial results show a 72.7% response rate and 90.9% disease control rate, with more data expected in 2023.